Generalist agencies lack understanding of peptide advertising restrictions, compliance language requirements, and the platform policies specific to research chemicals and high-risk health-adjacent categories. A campaign built without this knowledge triggers ad disapprovals, policy warnings, and eventually permanent account suspensions — resulting in lost ad accounts, lost revenue, and months of rebuild time. Ads Digitally applies compliance-first frameworks across every campaign element before anything goes live.

Yes — within strict compliance frameworks. Meta and Google both permit research-oriented peptide advertising when campaigns avoid direct health claims, use compliant audience targeting, and follow platform-specific creative guidelines. The MHRA, FDA, Health Canada, and TGA each impose additional restrictions on how peptide products are described. Ads Digitally builds every campaign within these dual-layer compliance requirements. Our clients have maintained active accounts with zero platform shutdowns since 2023.

Ads Digitally works exclusively with research peptide brands in four regulated markets: the United Kingdom (MHRA compliance), the United States (FDA compliance), Canada (Health Canada compliance), and Australia (TGA compliance). Every marketing system — paid ads, SEO, email, and CRO — is built around the specific regulatory requirements of each market.

We prevent ad account bans through three mechanisms. First, every campaign uses policy-reviewed creative avoiding language and claims known to trigger platform flags. Second, account structures include compliance checkpoints that identify risk before ads go live. Third, our monitoring systems detect platform policy changes and update active campaigns in advance of enforcement. Our record: zero platform shutdowns across all active client accounts since the agency's founding in 2023.

Our compliance review process is specifically designed to prevent account-level issues by catching policy violations before they reach platform review. In the event of a flagging incident, we conduct a rapid policy audit, implement remediation steps, and manage the appeals process. We have maintained a 100% platform account retention rate across all active client accounts since 2023.

Our agency has direct marketing experience with BPC-157, TB-500, Ipamorelin, CJC-1295, GHRP-6, Tirzepatide, Semaglutide, Retatrutide, Hexarelin, GHK-Cu, AOD-9604, and other research peptide compounds sold legally as research-use-only products. Each compound has specific compliance requirements that our campaigns are engineered around.

Compliant paid advertising campaigns generate qualified traffic within 2–4 weeks of launch. Peptide-specific SEO produces meaningful organic ranking movement within 3–6 months of consistent execution. Email and retention systems show measurable LTV improvement within 60–90 days. Timelines vary based on market, competition, and starting domain/account conditions.